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symptoms and sexual dysfunction. We therefore sought to evaluate for relevant associations among a cohort of men presenting to a sexual health clinic with concomitant depressive symptoms.
METHODS: We collected data on all consecutive men undergoing evaluation for sexual health concerns in a men's sexual health clinic between March 2014 and October 2016 at our institution. Detailed information was obtained on topics including relationships, libido, erectile dysfunction, premature and delayed ejaculation and International Index of Erectile Function (IIEF) scores. Data regarding pertinent medical, surgical and social history was also collected. Statistical analysis was performed to evaluate for significant associations between patients reporting depressive symptoms and information on other sexual dysfunctions.
RESULTS: A total of 884 patients had data available on depressive symptoms and complete sexual function information. Of the cohort, mean IIEF scores were 29.3, and 207 (23%) endorsed depressive symptoms. Among patients reporting depressive symptoms, the most common presenting concerns included erectile dysfunction (75%), penile curvature (28%), low libido/hypogonadism (24%), low testosterone (20%) and ejaculatory dysfunction (10%)(>100% due to more than one concern permitted). Univariate analysis identified lower total IIEF scores (mean 25.9) in men with depressive symptoms compared to those without (mean 30.3, p¼0.008). Interestingly, on subgroup analysis, depressive symptoms failed to significantly correlate with the erectile function domain (p¼0.10), but did correlate with the orgasmic function (p<0.01), sexual desire(p<0.01), intercourse satisfaction (p<0.01), and the overall satisfaction domains (p<0.0001). Additionally, patients with depressive symptoms were more likely to report that their sexual dysfunction negatively impacted their relationships (p<0.01) and had significantly shorter relationships than those without similar symptoms (20.7 years vs. 25.3 years, respectively, p<0.01).Patients reporting depressive symptoms also reported significantly lower intercourse frequency per month (3.4 vs. 4.5, respectively, p¼0.01).
CONCLUSIONS: Patients who reported depressive symptoms had significantly lower IIEF scores, including reduced orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction domains without significant differences in the erectile function domain. Additionally, these patients had shorter relationships, lower intercourse frequency and were more likely to report that their sexual dysfunction negatively impacted their relationships. These intriguing findings highlight novel areas of potential future research for the impact of mental health on sexual dysfunctions.
Source of Funding: none

MP84-10
INTRODUCTION AND OBJECTIVES: The risk of erectile dysfunction (ED) increases with age and typically occurs in middle and older aged men. Recently, we have experienced an increase in young men referred to our practice for ED, with many of these men also complaining of symptoms of low testosterone. Given the paucity of data on this subject, we sought to describe the hormonal profiles of young men with the chief complaint of ED. We hypothesize that the majority of young men with ED will have normal hormonal evaluations.
METHODS: Institutional Review Board (IRB) approval was obtained for a retrospective chart review of men aged 18-40 years who presented with the complaint of ED and had a hormonal evaluation from January 2002-October 2016 at a tertiary care institution. We obtained data on demographics, co-morbidities, medications, and hormonal evaluations. Hypogonadism was defined as a testosterone level <200 ng/dL and hyperprolactinemia as a prolactin level >13.1 ng/mL. RESULTS: A total of 2,292 men were identified. The median age was 32.7 years with more men complaining of ED as they neared age 40 compared to younger ages. 42.9% of men were White, 8.6% Black or African American, 4% Asian, 0.9% Hispanic, and 43.6% other or unknown. Median BMI was 26.8. The most common comorbidities are listed in Table 1 . Men were being actively treated for these medical conditions. Additionally, 9% of men were taking antihistamines, 6.10% using H2-receptor antagonists, and 9.9% taking muscle relaxants. The average total testosterone level was 368 AE 160 ng/dL. 10.6% of men had hypogonadism. Abnormalities of LH and FSH were noted in 10% and 9.1% of men, respectively. 8.5% of men had hyperprolactinemia. For treatment of ED, 68.7% of men were given a phosphodiesterase type 5 inhibitor (PDE5i) and 2.4% were given alprostadil. 12.9% of men were started on testosterone therapy.
CONCLUSIONS: The majority of men under age 40 with ED exhibit a normal hormonal milieu. Men of this cohort that endorsed symptoms of low testosterone may in fact be experiencing symptoms which could be attributed to life stressors or associated comorbidities such as depression, anxiety, or diabetes. Additionally, many men were using medications that have been linked to ED including antihypertensives, antihistamines, and H2-receptor antagonists. A majority of these men with ED were treated with a PDE5i.
Source of Funding: None
MP84-11 CALCULATED FREE T AND T:E RATIO BUT NOT TOTAL TESTOSTERONE AND ESTRADIOL PREDICT LOW LIBIDO
Nikhil Gupta*, Bradley Holland, Georgia Mueller, Tobias K€ ohler, Springfield, IL INTRODUCTION AND OBJECTIVES: Libido is thought to be influenced by hormonal milieu, particularly testosterone. The role of estradiol in male sexual function has grown in importance, with estradiol cut-point of 5 ng/dL in hypogonadal men thought to directly affect libido. We sought to assess the impact of sex hormones on libido in a cardiac patient population.
METHODS: 200 men in a cardiology practice completed IIEF-15, ADAM, and previous ED treatment questionnaires and had serum total testosterone (T), estradiol (E), and sex hormone binding globulin (SHBG) measured via morning lab draws. Free testosterone (CFT) was calculated using an online ISSM calculator. Patients previously treated for hypogonadism or who were on medications that could affect T were excluded. Answers to IIEF questions 11 and 12 (IIEF11, IIEF12), which concern libido, on a 5-point Likert scale were compared with hormone levels. Spearman correlations and multivariate logistic regression were performed to analyze end points.
RESULTS: Mean total T was 310 ng/dL, CFT was 5.4 ng/dL, mean E was 4.4 ng/dL, mean T:E ratio was 8.2. 55% of subjects had T < 300 ng/dL. 74% of subjects had CFT < 6.5 ng/dL. Negative correlation was found between estradiol and IIEF11 and IIEF12, which did not reach statistical significance (p¼0.08). Positive correlation was found between IIEF11 and IIEF12 and CFT and T:E ratio (p¼0.007, p¼0.009) At a cutoff of E¼5ng/dL, no difference was found for either hypogonadal or eugonadal men on IIEF11 or IIEF12 (p¼0.50, p¼0.71). Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1143
